Predictive value of ITPA polymorphism in the treatment of chronic hepatitis С
I.G. BAKULIN, A.A. VARLAMICHEVA
Central Scientific Research Institute of Gastroenterology of Moscow Clinical Scientific Center, 86 shosse Entuziastov, 86, Moscow, Russian Federation, 111123
Bakulin I.G.— D. Med. Sc., Professor, Head of the Department of Hepatology, tel. +7-925-518-65-38, e-mail: igbakulin@yandex.ru
Varlamicheva A.A.— Junior Researcher of the Department of Chronic Liver Disease № 1, tel. +7-916-298-52-86, e-mail: annvarl@mail.ru
Тhe report given is devoted to the discussion of the inosine triphosphanatase (ITPA) gene effect on the development of the most common adverse event (AE), namely the ribavirin (RBV) — induced anemia during the antiviral is the therapy as well as to the problem how to achieve a stable viral response (SVR) in patients with hepatitis C virus. The main problem under the RBV development is the necessity to modify the dose, which may result in reduction of therapy efficacy and the increase of the recurrence rate. From the point of view of medical practice it is extremely important forecast and prevent bad anemia as well as to follow carefully the treatment management strategy in the risk group patients.
Key words: ribavirin, anemia, antiviral therapy, SNP, ITPA, inosine triphosphatase.
REFERENCES
1. Romero-Gomez M., Eslam M., Ruiz A., Maraver M. Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. J. Liver International, 2011, pp. 443-460.
2. Rau M., Baur K., Geier A. Host Genetic Variants in the Pathogenesis of Hepatitis C. J Viruses, 2012, vol. 4, pp. 3281-3302. DOI:10.3390/v4123281.
3. Bakulin I.G., Fedulenkova L.V., Sidorova I.O. The safety of boceprevir and telaprevir as a part of antiviral therapy of chronic hepatitis C. Gepatologicheskiy forum, 2012, vol. 2, pp. 16-20 (in Russ.).
4. McHutchison J.G., Lawitz E.J., Shiffman M.L. et al. IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med., 2009, vol. 36, pp. 580-589.
5. Poordad F., McCone J., Bacon B.R. et al. SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med., 2011, vol. 364, pp. 1195-1206.
6. Bacon B.R., Gordon S.C., Lawitz E. et al. HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med., 2011, vol. 364, pp. 1207-1217.
7. Jacobson I.M., McHutchison J.G., Dusheiko G. et al. ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med., 2011,vol. 364, pp. 2405-2416.
8. Zeuzem S., Andreone P., Pol S. et al. REALIZE Study Team. Telaprevir for retreatment of HCV infection. N. Engl. J. Med., 2011, vol. 364, pp. 2417-2428.
9. Reichard O., Norkrans G., Frydén A., Braconier J.H. et al. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C: the Swedish Study Group. J. Lancet., 1998, vol. 351, pp. 83-87.
10. Brok J., Gluud L.L., Gluud C. Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane Hepato-Biliary Group systematic review and meta-analysis of randomized trials. Am. J. Gastroenterol., 2006, vol. 101, pp. 842-847.
11. COPEGUS® (ribavirin) Tablets Initial U.S. Approval: 2002.
12. Ira M. Jacobson, Kris V. Anemia Management in the Era of Triple Combination Therapy for Chronic HCV. Gastroenterol. Hepatol. (N Y)., 2012 September, vol. 8 (9 Suppl 6), pp. 1-16.
13. Krishnan S.M., Dixit N.M. Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy. PLoS Comput Biol., 2011, vol. 7, pp e1001072.
14. Russmann S., Grattagliano I., Portincasa P., Palmieri V.O., Palasciano G. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr. Med. Chem., 2006, vol. 13, pp. 3351-3357.
15. McHutchison J.G., Manns M., Patel K., Poynard T., Lindsay K.L., Trepo C. et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology, 2002, vol. 123, pp. 1061-1069.
16. Reddy K.R., Nelson D.R., Zeuzem S. Ribavirin: current role in the optimal clinical management of chronic hepatitis C. J. Hepatol., 2009, vol. 50, pp. 402-411.
17. De Franceschi L., Fattovich G., Turrini F., Ayi K. et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology, 2000, vol. 31, pp. 997-1004.
18. Shipkova M., Lorenz K., Oellerich M., Wieland E., Nicolas von Ahsen. Measurement of Erythrocyte Inosine Triphosphate Pyrophosphohydrolase (ITPA) Activity by HPLC and Correlation of ITPA Genotype-Phenotype in a Caucasian Population. Clinical Chemistry, 2006, vol. 52, № 2, pp. 240-247.
19. Thompson A.J., Fellay J., Patel K., Tillmann H.L. et al. Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia and Decrease the Need for Ribavirin Dose Reduction. J. Gastroenterology, 2010, vol. 139, pp. 1181-1189.
20. Miyamura T., Kanda T., Nakamoto S., Wu S. et al. Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin. J. Viruses., 2012, vol. 4, pp. 1264-1278. DOI:10.3390/v4081264.
21. Tsubota A., Shimada N., Abe H., Yoshizawa K. et al. Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C. World J. Gastroenterology. 2012 November 7, vol. 18, № 41, pp. 5879-5888 ISSN 1007-9327 (print) ISSN 2219-2840.
22. Seto W.-K., Tsang O. T.-Y., Liu K., Chan J. M.-C. et al. Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection. J. of viral hepatitis, 2013, vol. 20, № 7, pp. 470-7.
23. Eskesen A.N., Melum E., Moghaddam A., Bjoro K. et al. Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort. European Journal of Gastroenterology & Hepatology, 2012 Aug., vol. 24, № 8, pp. 890-6.
24. Di Marco V., Calvaruso V., Grimaudo S., Ferraro D. et al. Role of IL-28B and Inosine Triphosphatase Polymorphisms in Efficacy and Safety of Peg-Interferon and Ribavirin in Chronic Hepatitis C Compensated Cirrhosis With and Without Oesophageal Varices. J. Viral Hepat., 2013, vol. 20, № 2, pp. 113-121.
25. Sulkowski M.S., Shiffman M.L., Afdhal N.H. et al. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate // Gastroenterology. — 2010. — Vol. 139. — Р. 1602-1611.
26. Victrelis (boceprevir) [package insert]. Whitehouse Station, PA: Merck & Co., Inc; 2012.
27. Incivek (telaprevir) [package insert]. Cambridge, MA: Vertex Pharmaceuticals; 2012.
28. Hézode C., Dorival C., Zoulim F. et al. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non responders. First Results of the French Early Access Program (ANRS CO20-CUPIC) in real-life setting. Presented at HepDART. 2011 December 4-8. Kauai, Hawaii. Abstract 46.
29. Sulkowski M., Poordad F., Manns M.P. et al. Anemia during treatment with peginterferon alfa-2b/ribavirin with or without boceprevir is associated with higher SVR rates: analysis of previously untreated and previous-treatment-failure patients. J. Hepatol., 2011, vol. 54 (suppl.1), pp. S195-S196.
30. Roberts S., Andreone P., Pol S. et al. Impact of anemia and ribavirin dose reduction on SVR in a telaprevir-based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure in the phase III REALIZE study. AASLD; November 4-8, 2011, San Francisco, California, Abstract 1366.
31. Sulkowski M.S., Reddy R., Afdhal N.H. et al. Anemia had no effect on efficacy outcomes in treatment-naive patients who received telaprevir-based regimens in the ADVANCE and ILLUMINATE phase 3 studies. J. Hepatol., 2011, vol. 54 (suppl 1), pp. S195.
32. Sherman K.E., Flamm S.L., Afdhal N.H. et al. ILLUMINATE Study Team. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med., 2011, vol. 365, pp. 1014-1024.
33. D’Avolio A., Ciancio A., Siccardi M., Smedile A. et al. Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment // Therapeutic Drug Monitoring. — 2012 Apr. — Vol. 34, № 2. — Р. 165-70.
34. Chayama K., Hayes N., Abe H., Miki D. et al. IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C. JID, 2011, pp. 204.
35. Kobayashi T., Hige S., Terashita K., Nakai M. et al. Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C. Journal of Gastroenterology, 2012 Nov., vol. 47, № 11, pp. 1228-37.
36. Peck-Radosavljevic M., Wichlas M., Homoncik-Kraml M. et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. J. Gastroenterology, 2002, vol. 123, pp. 141-151.
37. Suzuki F., Suzuki Y., Akuta N., Sezaki H. et al. Influence of ITPA Polymorphisms on Decreases of Hemoglobin During Treatment with Pegylated Interferon, Ribavirin, and Telaprevir. J. Hepatology, 2011 February, pp. 415-420.